Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
ME D’Amico, E Silvagni, G Carrara, A Zanetti, M Govoni, CA Scirè & A Bortoluzzi. (2021) Role of comorbidities on therapeutic persistence of biological agents in rheumatoid arthritis: results from the RECord-linkage On Rheumatic Disease study on administrative healthcare databases. Scandinavian Journal of Rheumatology 50:5, pages 333-342.
Read now
Read now
Jean-Guillaume Letarouilly, Jean-Hugues Salmon & René-Marc Flipo. (2021) Factors affecting persistence with biologic treatments in patients with rheumatoid arthritis: a systematic literature review. Expert Opinion on Drug Safety 20:9, pages 1087-1094.
Read now
Read now
Karin Luttropp, Johan Dalén, Axel Svedbom, Mary Dozier, Christopher M Black & Amy Puenpatom. (2020) Real-World Patient Experience of Switching Biologic Treatment in Inflammatory Arthritis and Ulcerative Colitis – A Systematic Literature Review. Patient Preference and Adherence 14, pages 309-320.
Read now
Read now
Valentin Brodszky, Anikó Bíró, Zoltán Szekanecz, Boglárka Soós, Petra Baji, Fanni Rencz, László Tóthfalusi, László Gulácsi & Márta Péntek. (2017) Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data. ClinicoEconomics and Outcomes Research 9, pages 139-147.
Read now
Read now
Articles from other publishers (21)
Stefka Neycheva, Emilia Naseva, Zguro Batalov, Rositsa Karalilova & Anastas Batalov. (2023) First multi-center retrospective study assessed the compliance with and persistence of biological therapies in Bulgarian population with rheumatoid arthritis. Rheumatology International 43:12, pages 2233-2243.
Crossref
Crossref
Vered Rosenberg, Gabriel Chodick, Zhenyi Xue, Freddy Faccin & Howard Amital. (2023) Real-World Data of Adherence and Drug Survival of Biologics in Treatment-Naïve and Treatment-experienced Adult Patients with Rheumatoid Arthritis. Advances in Therapy.
Crossref
Crossref
Beliz KARATAŞ & Barış YILMAZER. (2023) Factors Affecting Survival on Biologic Treatments in Patients with Rheumatoid Arthritis: A Single-Center Study From TurkeyRomatoid Artrit Tanılı Hastalarda Biyolojik İlaç Sağkalımını Etkileyen Faktörler: Türkiye’den Tek Merkezli Bir Çalışma. Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi 18:1, pages 73-84.
Crossref
Crossref
Sara Bayat, Koray Tascilar, Daniela Bohr, Gerhard Krönke, David Simon, Johannes Knitza, Fabian Hartmann, Georg Schett & Arnd Kleyer. (2022) Efficacy and drug persistence of baricitinib monotherapy is similar to combination therapy in patients with active RA: a prospective observational study. RMD Open 8:2, pages e002674.
Crossref
Crossref
John Fitton, Andrew Melville, Kamran Naraghi, Jacqueline Nam, Shouvik Dass, Paul Emery & Maya H Buch. (2022) Single-centre experience of refractory rheumatoid arthritis. Rheumatology Advances in Practice 6:2.
Crossref
Crossref
Zulema Rosales Rosado, Judit Font Urgelles, Isabel Hernández Rodríguez, Leticia León Mateos, Lydia Abásolo Alcázar & Juan Ángel Jover Jover. (2022) Clinical management and discontinuation of treatment in patients with recent onset rheumatoid arthritis in a rheumatology consultation. Reumatología Clínica (English Edition) 18:2, pages 77-83.
Crossref
Crossref
Zulema Rosales Rosado, Judit Font Urgelles, Isabel Hernández Rodríguez, Leticia León Mateos, Lydia Abásolo Alcázar & Juan Ángel Jover Jover. (2022) Manejo clínico y discontinuación de tratamiento en pacientes con artritis reumatoide de inicio en una consulta de Reumatología. Reumatología Clínica 18:2, pages 77-83.
Crossref
Crossref
Jesús Tornero-Molina, Mercedes Alperi-López, Ivan Castellví, Juan José de Agustín-de Oro, Alejandro Escudero, Rosario García-Vicuña, Miguel Ángel González-Gay, Cristina Hidalgo, Esteban Rubio, Raimon Sanmartí, Núria Casamira & Jaime Calvo-Alén. (2022) Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis. Reumatología Clínica (English Edition) 18:1, pages 33-41.
Crossref
Crossref
Jesús Tornero-Molina, Mercedes Alperi-López, Ivan Castellví, Juan José de Agustín-de Oro, Alejandro Escudero, Rosario García-Vicuña, Miguel Ángel González-Gay, Cristina Hidalgo, Esteban Rubio, Raimon Sanmartí, Núria Casamira & Jaime Calvo-Alén. (2022) Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis. Reumatología Clínica 18:1, pages 33-41.
Crossref
Crossref
Yi Ru, Xiaojie Ding, Ying Luo, Hongjin Li, Xiaoying Sun, Mi Zhou, Yaqiong Zhou, Le Kuai, Meng Xing, Liu Liu, Yue Luo, Jiankun Song, Jiale Chen, Bin Li & Xin Li. (2021) Adverse Events Associated With Anti-IL-23 Agents: Clinical Evidence and Possible Mechanisms. Frontiers in Immunology 12.
Crossref
Crossref
Dalifer Freites-Núñez, Athan Baillet, Luis Rodriguez-Rodriguez, Minh Vu Chuong Nguyen, Isidoro Gonzalez, Jose Luis Pablos, Alejandro Balsa, Monica Vazquez, Philippe Gaudin & Benjamín Fernandez-Gutierrez. (2020) Efficacy, safety and cost-effectiveness of a web-based platform delivering the results of a biomarker-based predictive model of biotherapy response for rheumatoid arthritis patients: a protocol for a randomized multicenter single-blind active controlled clinical trial (PREDIRA). Trials 21:1.
Crossref
Crossref
Iciar Cañamares Orbis, Leticia Merino Meléndez, Irene Llorente Cubas, Juana Benedí González, Rosario García-Vicuña, Alberto Morell Baladrón, Isidoro González-Álvaro & Esther Ramírez Herraiz. (2020) Factores asociados a la persistencia a largo plazo de rituximab en artritis reumatoide en la práctica clínica: Estudio RITAR. Medicina Clínica 155:1, pages 1-8.
Crossref
Crossref
Iciar Cañamares Orbis, Leticia Merino Meléndez, Irene Llorente Cubas, Juana Benedí González, Rosario García-Vicuña, Alberto Morell Baladrón, Isidoro González-Álvaro & Esther Ramírez Herraiz. (2020) Factors associated with long-term persistence of rituximab in rheumatoid arthritis in clinical practice: RITAR Study. Medicina Clínica (English Edition) 155:1, pages 1-8.
Crossref
Crossref
Peter Peichl, Rieke Alten, Mauro Galeazzi, Hanns-Martin Lorenz, Hubert Nüßlein, Federico Navarro, Yedid Elbez, Melanie Chartier, Roland Hackl, Christiane Rauch & Sean E Connolly. (2019) Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION studyAbatacepttherapietreue und klinische Ergebnisse bei Patienten mit rheumatoider Arthritis in Österreich: 2-Jahres-Daten der ACTION-Studie aus dem Praxisalltag. Wiener Medizinische Wochenschrift 170:5-6, pages 132-140.
Crossref
Crossref
Janet E. Pope, Edward Keystone, Shahin Jamal, Lisy Wang, Lara Fallon, John Woolcott, Irina Lazariciu, Douglass Chapman & Boulos Haraoui. (2019) Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years. ACR Open Rheumatology 1:2, pages 73-82.
Crossref
Crossref
Alessandro Sartini, Eleonora Scaioli, Elisa Liverani, Matteo Bellanova, Luigi Ricciardiello, Franco Bazzoli & Andrea Belluzzi. (2018) Retention Rate, Persistence and Safety of Adalimumab in Inflammatory Bowel Disease: A Real-Life, 9-Year, Single-Center Experience in Italy. Digestive Diseases and Sciences 64:3, pages 863-874.
Crossref
Crossref
Rene Westhovens. (2019) Clinical efficacy of new JAK inhibitors under development. Just more of the same?. Rheumatology 58:Supplement_1, pages i27-i33.
Crossref
Crossref
Christos G Papadopoulos, Ilias K Gartzonikas, Tatiani K Pappa, Theodora E Markatseli, Michael P Migkos, Paraskevi V Voulgari & Alexandros A Drosos. (2019) Eight-year survival study of first-line tumour necrosis factor α inhibitors in rheumatoid arthritis: real-world data from a university centre registry. Rheumatology Advances in Practice 3:1.
Crossref
Crossref
Noelia Alvarez Rivas, Tomas R. Vazquez Rodriguez, Jose A. Miranda Filloy, Carlos Garcia-Porrua & Amalia Sanchez-Andrade Fernández. (2019) Long-term Survival of Subcutaneous Anti-tumor Necrosis Factor Biological Drugs Administered Between 2008 and 2012 in a Cohort of Rheumatoid Arthritis Patients. Reumatología Clínica (English Edition) 15:1, pages 54-57.
Crossref
Crossref
Noelia Alvarez Rivas, Tomas R. Vazquez Rodriguez, Jose A. Miranda Filloy, Carlos Garcia-Porrua & Amalia Sanchez-Andrade Fernández. (2019) Supervivencia a largo plazo de los fármacos biológicos anti-TNF subcutáneos administrados durante los años 2008-2012 en una cohorte de pacientes con artritis reumatoide. Reumatología Clínica 15:1, pages 54-57.
Crossref
Crossref
Bruce Carrington, William K. Myers, Peter Horanyi, Mark Calmiano & Alastair D.G. Lawson. (2017) Natural Conformational Sampling of Human TNFα Visualized by Double Electron-Electron Resonance. Biophysical Journal 113:2, pages 371-380.
Crossref
Crossref